Diagnostic News: Breaking Diagnostic News, Comments and Articles. - Page: 5

AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies

SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications.  Under the terms of AnaptysBio's contract with the Science and Technology Corporation, AnaptysBio will be responsible...

Depression and time perception: an interview with Dr Rachel Msetfi, University of Limerick

In clinical terms, depression is defined by the presence of a cluster of symptoms. The Diagnostic Manual used by many psychologists and psychiatrists cites nine symptoms of depression, of which five must be present for a two-week period.

Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook

Companion diagnostics in oncology – Key questions manufacturers should ask to prepare for market access New York, NY (PRWEB) May 16, 2013 Leading UK company, PRMA Consulting launches PRMA Insights: Market Access Success for Companion Diagnostic–Drug Pairings in Oncology, a unique handbook that addresses the key issues that biopharmaceutical manufacturers should understand when developing new...

NYS Licensed Psychologist Releases Internet Safety Tool for Mental Health Professionals

An exhaustive mental health internet safety checklist has been released for purchase by iPredator Inc. Developed by Michael Nuccitelli Psy.D., C.F.C., a New York State licensed psychologist and certified forensic consultant, this risk assessment and diagnostic tool was designed to assist psychologists, psychiatrists and behavioral healthcare professionals formulate accurate diagnoses, create indiv...

£40,000 awarded to innovative service development

Central Manchester University Hospitals NHS Foundation Trust (CMFT), alongside their partner MIMIT™, has awarded £40,000 as part of a new innovative award scheme.The CMFT Clinical Need Award was created, with a generous donation from the...

Nordion, Navidea sign contract manufacturing agreement

Nordion has entered into a contract manufacturing agreement with Navidea Biopharmaceuticals for NAV5001 a diagnostic imaging agent used to detect Parkinsonian Syndromes and Dementia with Lewy Bodies.

Synthetic analog computation in living cells

A central goal of synthetic biology is to achieve multi-signal integration and processing in living cells for diagnostic, therapeutic and biotechnology applications. Digital logic has been used to build small-scale circuits, but other frameworks may...

New Validation and Clinical Outcome Data From Several Studies on Nanosphere's Gram-Positive and Gram-Negative Blood Culture Tests to Be Presented at ASM 2013

NORTHBROOK, IL -- (Marketwired) -- 05/16/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that new validation and outcome data for select Verigene® clinical microbiology tests will be presented at the 113th General Meeting of the American Society for Microbiology (ASM) being held in Denver, CO fro...

Daxor Corporation Announces Placement of BVA-100 Blood Volume Analyzer at Austin Nuclear Pharmacy, Inc.

NEW YORK, NY -- (Marketwired) -- 05/16/13 -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced today that Austin Nuclear Pharmacy, Inc. has leased a BVA-100 Blood Volume Analyzer. Austin Nuclear Pharmacy, Inc., established in 2002, is an independently owned and operated nuclear pharmacy which specializes in providing pro...

Brockville General Hospital Acquires Canada's First State-of-the-Art Sysmex XN-2000(TM) Automated Hematology Analyzer

BROCKVILLE, ON -- (Marketwired) -- 05/16/13 -- Ontario-based Brockville General Hospital and Sysmex Canada, Inc. today announced the hospital's installation and implementation of a Sysmex XN-2000™ Automated Hematology Analyzer. This is the first analyzer of the new Sysmex® XN-Series suite of products to be installed in Canada. This revolutionary compact automated hematology analyzer provides th...

Neuro Kinetics in Tech Transfer Licensing Deal With Oregon Health & Science University

PITTSBURGH, PA -- (Marketwired) -- 05/16/13 -- Medical device manufacturer Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com) said today that it has licensed rights to patented diagnostic software developed at Oregon Health & Science University (OHSU) (www.ohsu.edu) that enables medical researchers to perform Pulse-Step-Sine Rotation tests to better understand vestibular system abnormalities...

Nordion, Navidea Sign Manufacturing Contract

Will cover manufacture and supply of diagnostic imaging agent for trials

AMI Research Initiates Coverage on Diagnostic Imaging International Corp. With a Speculative Buy Rating of $0.62

LAS VEGAS, NEVADA -- (Marketwired) -- 05/16/13 -- AMI Research, a leading provider of equity research reports and a subsidiary of Hawk Associates Inc., announced today that it has initiated equity research coverage on Diagnostic Imaging International Corp. (OTCQB: DIIG) with a Speculative Buy rating of $0.62 per share. AMI president Peter J. D'Agostino said, "We think DIIG is poised for substan...

Eutropics Pharmaceuticals to Present Data on Personalized Diagnostic for AML Patient Management at ASCO 2013

Study using Novel Biomarker Technology Indicates Potential Medical Utility in Discriminating Clinical Outcomes Eutropics Pharmaceuticals Inc. announced today that Eutropics and The University of Texas MD Anderson Cancer Center will present results from a clinical study employing Eutropics’ proprietary PraediCare Dx (BH3 profiling) assay to discrimina...

NanoString Technologies Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology (ASCO) Meeting on Sun...

Nordion Signs Contract Manufacturing Agreement with Navidea Biopharmaceuticals

Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today announced it has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals. Under terms of the agreement, Nordion will manufact...

Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion

– Nordion to Produce and Distribute Supplies of 123I-labeled Drug Product NAV5001 for Late-Phase Clinical Trials – Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has entered into an agreement with Nordion (Canada) Inc. to produce and supply...

Overinterpretation common in diagnostic accuracy studies

(HealthDay)—Roughly three in 10 diagnostic accuracy studies published in journals with impact factors of four or higher have overinterpretation, according to a review published in the May issue of Radiology.

Engineers monitor heart health using paper-thin flexible 'skin'

Most of us don't ponder our pulses outside of the gym. But doctors use the human pulse as a diagnostic tool to monitor heart health.Read more about Engineers monitor heart health using paper-thin flexible 'skin'

Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting

FLEMINGTON, N.J., May 15, 2013 /PRNewswire/ -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, which is being hel...

Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (A...

Genomic Health's New Prostate Test May Extend The Stock's Upward Climb

By Amy Baldwin:Genomic Health, Inc.'s (GHDX) stock has risen over 31% in the last month. The molecular diagnostics company's upward swing may be due to an earlier announcement of an 8% increase in revenue, but what probably propelled the stock further in the last few days was that Genomic health announced its novel genetic test to gauge the aggressiveness of prostate cancer became available on the...

NICE to produce briefings on technologies

The U.K.'s NICE said it will publish about 40 "Medtech Innovation Briefings" annually to provide objective information on devices and diagnostics to help boost the uptake of the technologies within NHS. The agency said the briefings will describe the...

Genentech reports Phase I data for MPDL3280A

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said IV MPDL3280A once every three weeks led to an objective response rate (ORR) of 21% in 140 patients with locally advanced or metastatic solid tumors whose disease had progressed despite prio...

Broader Indications For Tarceva As Astellas Scales Back In The U.S.

The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.